Current Report Filing (8-k)
May 23 2017 - 10:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
May 22, 2017
Ekso Bionics Holdings, Inc.
(Exact
Name of Registrant as specified in its charter)
Nevada
|
001-37854
|
99-0367049
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(510) 984-1761
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s name or former address,
if change since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (
see
General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
x
|
Item 2.05
|
Costs Associated with Exit or Disposal Activities
|
On May 22, 2017, Ekso Bionics Holdings,
Inc. (the “Company”) implemented a plan to streamline its operations and reduce its workforce by approximately 25%
in order to lower operating expenses and reduce cash burn.
The Company is offering severance benefits
to the affected employees, including cash severance payments, grants of restricted stock units, outplacement services and payment
of health care insurance premiums for specified periods. Each affected employee’s eligibility for the severance benefits
is contingent upon such employee’s execution of a separation agreement, which includes a general release of claims against
the Company.
The Company expects to record restructuring-related
expenses in 2017 of approximately $1.0 million related to termination benefit costs and other costs associated with the workforce
reduction. Approximately $0.8 million of these expenses are expected to represent cash expenditures, most of which will be expensed
and paid in the second quarter of 2017, with the remaining cash expenditures paid in the third quarter of 2017. The remaining approximately
$0.2 million are one-time, non-cash, stock-based compensation expenses and are expected to be expensed in the third quarter of
2017.
The charge that the Company expects to incur
in connection with these actions is subject to a number of assumptions, and actual results may differ. The Company may also incur
other charges not currently contemplated due to events that may occur as a result of, or associated with, the plan. The Company
expects to complete these actions by the end of the third quarter of 2017.
Forward-Looking Statements
Any statements contained in this Current Report on Form 8-K
that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without
limitation, statements regarding (i) the timing and amount of expenditures related to the workforce reduction and anticipated
costs savings, (ii) the plans and objectives of management for future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons, (iii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other financial items, (iv) the Company's future financial performance and
(v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking
statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized
because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements
as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking
statements or cause actual results to differ materially from expected or desired results may include, without limitation, the
timing of planned expense reductions, the Company's inability to obtain adequate financing to fund the Company's operations and
necessary to develop or enhance our technology, the significant length of time and resources associated with the development of
the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our
sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of
the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure
to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or
increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors
are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including, but
not limited to, its latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company does not undertake
to update these forward-looking statements.
|
Item 7.01
|
Regulation FD Disclosure
|
On May 23, 2017, the Company issued a press
release announcing the events described above. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information in this Item
7.01, including the exhibit attached hereto, is furnished pursuant to Item 7.01 and shall not be deemed “filed”
for any other purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be deemed incorporated by
reference into any filing under the Securities Act of 1933 or the Exchange Act of 1934 regardless of any general
incorporation language in such filing unless specifically provided otherwise.
|
Item 9.01
|
Financial Statements and Exhibits
|
|
99.1
|
Press release dated May 23, 2017
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
By:
|
/s/ Maximilian Scheder-Bieschin
|
|
Name:
|
Maximilian Scheder-Bieschin
|
|
Title:
|
Chief Financial Officer
|
Dated: May 23, 2017
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024